As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...

Equities researchers at StockNews.com started coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Get Free Report) in a research report issued on Sunday. The firm set a “hold” rating on the ...

DARZALEX has significant market potential as a leading monoclonal antibody for multiple myeloma treatment. Its approval in various combinations for both newly diagnosed and relapsed/refractory ...

A digital therapeutics start-up which uses augmented reality (AR) glasses to aid people suffering from disorders including Parkinson's disease and multiple sclerosis will this week announce a £ ...

RBC Capital analyst Leonid Timashev maintained a Hold rating on Design Therapeutics (DSGN – Research Report) today and set a price target of $5.00. The company’s shares opened today at $4.87.

MONTREAL, March 11, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has entered into a ...

The Air Products Foundation recently donated $120,000 to the Ascension Parks Foundation to improve a park in Sorrento. Construction at the park is slated to begin later this year, a news release said.

Sorrento Therapeutics, Inc, a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease ...

The 11-bedroom property at 3206 Point Nepean Road in Sorrento comes with a price guide of between $9 million and $9.9 million. Selling agent Chris Cain of JA Cain told Domain the home has been ...

MSFP reports stocks from MERCK, Fate Therapeutics, Sorrento Therapeutics, Moderna and received licensing fee from Kiadis Pharma. The remaining authors declare that the research was conducted in the ...